Skip to content
You are now leaving to visit

Akcea and Ionis Announce Submission of New Drug Application for Volanesorsen to the U.S. FDA

<p>CAMBRIDGE, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today